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In 18 months, 850 patients were referred to Muhammad Ali Parkinson Center (MAPC). Among them, 810 patients had typical
Parkinson disease (PD) and 212 had PD for ≤5 years. Among the 212 patients with early PD, 27 (12.7%) had freezing of gait (FOG).
Forty of the 850 had atypical parkinsonism. Among these 40 patients, all of whom had symptoms for ≤5 years, 12 (30.0%) had FOG.
FOG improved with levodopa in 21/27 patients with typical PD but did not improve in the 12 patients with atypical parkinsonism.
FOG was associated with falls in both groups of patients. We believe that FOG unresponsive to levodopa in typical PD resembles
FOG in atypical parkinsonism. We thus compared the 6 typical PD patients with FOG unresponsive to levodopa plus the 12
patients with atypical parkinsonism with the 21 patients with typical PD responsive to levodopa. We compared them by tests of
locomotion and postural stability. Among the patients with FOG unresponsive to levodopa, postural stability was more impaired
than locomotion. This finding leads us to believe that, in these patients, postural stability, not locomotion, is the principal problem
underlying FOG.
1. Introduction
Freezing of gait (FOG) is characterized by an inability to
walk in which the patient’s feet appear to be “stuck,” while
the upper body continues to move. The forward progression
of the feet is markedly reduced despite the intention to
walk [1]. FOG is usually precipitated by turning, by walking
through a doorway, by walking in a confined space, and by
dual tasking [1, 2]. Turning, walking through a doorway,
and walking in a confined space have in common rapid and
frequent shortening of step length [3, 4]. Because FOG is
characterized by a shortening step length, it is usually thought
of as a disorder of locomotion. But FOG is also characterized
by falls, suggesting it is also a disorder of postural stability
[1]. To study the influence of locomotion and postural
stability on FOG, we compared FOG in patients with typical
Parkinson disease (PD) and atypical parkinsonism, disorders
characterized by different degrees of impaired locomotion
and postural stability. Although the etiology, pathology,
and pathophysiology of these disorders are different, the
phenomenon of FOG appears similar.
FOG occurs in Parkinson’s disease (PD). Its prevalence
has been variously reported, depending on referral patterns
and themix of early and late disease patients. In a longitudinal
analysis of 800 patients with early, untreated PD, part of the
DATATOP study, 57 of 800 patients (7.1%) had FOG on entry,
and 193 patients (26%) had FOG upon completion of the
study [5]. In a cross-sectional analysis of a different series
by the same author, 318 of 990 patients (32%) had FOG [6].
FOG is more common late in PD, with as many as 91 of 172
patients (53%) demonstrating it [7]. FOG in PD sometimes
responds to levodopa and sometimes does not [5–7]. The
events preceding and during a freeze are characterized by a
decrease in step length, a decrease in range of movement of
the hips, knees, and ankles, and an increase in falls [1, 8–11]. In
a study of 401 PD patients seen in one year, 44 patients (11%)
fell repeatedly. Twenty-one of these patients (48%) had FOG
[8].
FOGoccurs in atypical parkinsonism disorders including
multiple-system atrophy (MSA), progressive supranuclear
palsy (PSP), Lewy body dementia (LBD), and normal pres-
sure hydrocephalus [1, 12]. FOG also occurs in progressive
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primary freezing of gait (PPFG), a disorder characterized by
freezing without evidence of PD [13, 14]. It is unclear if PPFG
is a separate disorder or is part of the spectrum of disorder of
PSP [13, 14]. PPFG does not respond to levodopa.
Atypical parkinsonism progresses more rapidly than PD,
andmost patients with atypical parkinsonism, unlike patients
with PD, are disabled in 10 years or less. To compare FOG
in atypical parkinsonism and typical PD, we chose those
patients who had been diagnosed with atypical parkinsonism
or typical PD for five years or less.
2. Materials and Methods
In an 18-month period, January 1, 2013, to June 30, 2014, we
saw 850 new patients, who were referred with a diagnosis of
PDor atypical parkinsonism.Of these, 212 patients (25%) had
PD ≤ 5 years, and 27 of the 212 had FOG.Thus 13% of the 212
patients with early PD had FOG. All 27 patients improved
on levodopa. Ten of the 27 patients (37%) had dyskinesia. Of
the 27 patients, FOG improved on levodopa treatment in 21
(78%). In six patients, FOG did not improve on levodopa.
Fifteen patients (56%) fell repeatedly.
Among the 850 patients, 40 patients (4.7%) were diag-
nosed as having atypical parkinsonism. All 40 had their
disorder for ≤ five years. Two patients were diagnosed with
LBD, three with PPFG, three with MSA, and four with
PSP. Twelve of the 40 patients with atypical parkinsonism
had FOG. All 12 patients fell repeatedly. These 12 atypical
parkinsonism patients had at one time been on levodopa for
at least fourmonths. TwoMSApatients had briefly responded
to levodopa. At the time of the analysis, none of the 12 atypical
patients were on levodopa.
Accepted criteria were used to diagnose typical PD [15,
16] and atypical parkinsonism [17–19]. Patients with typical
PD were assessed using the motor portion of the MDS-
UPDRS [20, 21]. FOG was assessed using the five-point
(from 0 to 4) FOG subtest of the UPDRS. A score of ≥2
was considered abnormal. Locomotion was assessed using
the five-point gait subtest of the UPDRS. A score of ≥2
was considered abnormal. Locomotion was also assessed by
having the patient walk 7.67meters (25 feet) and counting the
number of steps the patient took [9]. Postural stability was
assessed using the five-point “pull subtest” of the UPDRS. A
score of ≥3 was considered abnormal. Postural stability was
also assessed by asking the patient to stand on one leg. An
inability to stand on either leg for <3 seconds was considered
abnormal [22]. Patients were also compared using the six-
point (from 0 to 5) Hoehn and Yahr scale.
All 27 typical PD patients were on levodopa and all had
responded as determined by a 30% or greater decrease in the
motor portion of the MDS-UPDRS. All 27 patients had been
evaluated in an “off” state 16 hours after their last levodopa
dose. All had FOG in their “off” state. All were then given
a test dose of levodopa up to 200% of their usual dose.
They were then evaluated in their “on” state. Among the 27
patients, FOG improved in 21 (78%). FOG did not improve
in 6 patients (22%). We studied three groups of patients with
FOG:
(1) a group of 12 atypical parkinsonism patients whose
FOG did not respond to levodopa: these patients fell
repeatedly (>2 falls per month);
(2) a group of 6 typical PD patients whose FOG did not
respond to levodopa: these patients fell repeatedly (≥2
falls per month);
(3) a group of 21 PD patients whose FOG did respond
to levodopa: these patients fell less often (≤1 fall per
month).
Although there are anatomical, pathological, and struc-
tural differences between the atypical parkinsonism and the
typical PD patients, we grouped the 6 typical PD patients
whose FOG did not respond to levodopa with the 12 atyp-
ical parkinsonism patients whose FOG did not respond to
levodopa, consolidating the three groups into two. We then
compared these 18 patients to the 21 typical PDpatientswhose
FOG did respond to levodopa (Tables 1 and 2).
We compared age, disease duration, falls, and step length
between both groups using a 2-tailed t-test at the 0.05 level
of significance. We compared the five-point Hoehn and Yahr
staging system, the five-point FOG subtest, the five-point
“pull subtest,” the five-point gait subtest, and the ability or
inability to stand on one foot for < 3 seconds with odds ratios
using MedCalc, version 14.17.0 (MedCalc Software, Ostend,
Belgium).
All patients were informed that their evaluations might
be used in scientific publications but that they, personally,
could not be identified.The retrospective study was approved
by the Institutional Review Board of St. Joseph’s Hospital and
Medical Center in Phoenix, Arizona, USA.
3. Results
In Table 1, age, disease duration, and Hoehn and Yahr stage
are compared between the 18 patients whose FOG did not
respond to levodopa and the 21 patients whose FOG did
respond to levodopa. Disease duration was significantly
shorter in the 18 patients whose FOG did not respond to
levodopa. Clinically, the importance of the observation is
moot, because we chose only patients who had their disease
for ≤ five years. Hoehn and Yahr stage was significantly worse
in the group of 18 patients whose FOG did not respond to
levodopa, and falls were more frequent.
In Table 2, FOG, the “pull subtest,” and the ability to stand
onone footwere significantlyworse in the group of 18 patients
whose FOG did not respond to levodopa. Step length was
significantly decreased (worse) in this group.The gait subtests
were similar. Tests of postural stability, the “pull subtest,” and
the ability to stand on one foot were more impaired than tests
of locomotion, that is, the gait subtest and step length.
4. Discussion
Patients with atypical parkinsonism and patients with typical
PD whose FOG did not respond to levodopa have a more
“debilitating” disorder than patients with typical PD whose
FOG did respond to levodopa. The patients whose FOG
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Table 1: Demographics of freezing of gait (FOG) patients unresponsive to levodopa compared to those of FOG patients responsive to
levodopa.
Patient demographics
FOG patients
unresponsive to
levodopa (𝑁 = 18)∗
FOG patients
responsive to
levodopa (𝑁 = 21)
Significance†
Age (yrs) 66.9 ± 7.1 67.4 ± 6.7 NS
Disease duration (yrs) 3.6 ± 0.9 4.2 ± 0.7 𝑃 = 0.036
Hoehn and Yahr stage ≥4 7/18 2/21
Odds ratio
6.05,
95% CI 1.06–34.4;
𝑃 = 0.043
≥2 falls/month 15/18 11/21
Odds ratio
4.6,
95% CI 1.01–20.5;
𝑃 = 0.05
∗In the group, 12 patients had atypical parkinsonism and 6 had PD.
†Significant values are indicated in bold.
FOG: freezing of gait; PD: Parkinson’s disease.
Table 2: Results of postural stability and locomotion tests on freezing of gait (FOG) patients unresponsive to levodopa compared to patients
responsive to levodopa.
Tests
FOG patients unresponsive
to levodopa (𝑁 = 18)
Number Abnl Test/total
number
FOG patients responsive to
levodopa (𝑁 = 21)
Number Abnl Test/total
number
Significance†
FOG subtest >2 11/18 4/21
Odds ratio
6.7, 95% CI 1.58–28.3;
𝑃 = 0.01
Pull subtest ≥3 15/18 11/21
Odds ratio
4.6, 95% CI 1.00–20.5;
𝑃 = 0.05
Stand on one leg <3 seconds 15/18 11/21
Odds ratio
4.6, 95% CI 3.1–20.1;
𝑃 = 0.05
Gait subtest ≥2 10/18 6/21
Odds ratio
3.1;
NS
Step length (meters) 0.45 ± 0.06 0.50 ± 0.404 𝑃 = 0.05
Abnl: abnormal; FOG: freezing of gait.
†Significant values are indicated in bold.
did not respond to levodopa fell more frequently and had
a significantly higher (worse) Hoehn and Yahr stage, signif-
icantly more impaired postural stability as assessed by the
“pull subtest,” and the ability to stand on one leg. Locomotion
as assessed by step length and the gait subtest were less
impaired. We interpret this as implying that postural stability
is compromised more than locomotion and that a deficiency
in postural stability may be the principal problem in FOG.
The basic pattern of locomotion, the rhythmical move-
ment of the legs, is generated in the spinal cord. Cen-
tral pattern generators for locomotion are neural networks
spread over several spinal segments [1, 18, 19]. A hierarchy
of supraspinal centers sends descending commands to the
spinal central pattern generators. This supraspinal command
network is necessary for initiating gait, turning, stopping,
and avoiding obstacles [1, 18, 19]. The spinal central pattern
generators for locomotion plus the supraspinal command
system constitute the locomotor network.
The locomotor network probably interacts with a postural
stability network that includes position sensors in muscles
and tendons, the otoliths and statoliths, the vestibular nuclei,
the pedunculopontine nuclei (PPN), the basal ganglia, the
thalami, and the frontal and parietal lobes [23–32]. The
locomotor and balance networks include the limbic system,
which may explain, in part, the association of FOG with
anxiety [33, 34].
FOG in typical PD initially responds to levodopa but later
may not [35–42]. This suggests that, as PD progresses, non-
dopaminergic (noradrenergic, cholinergic) and dopaminer-
gic systems are disrupted.
The locomotor and postural stability networks include
the PPN [43, 44], which are disrupted in typical PD and
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atypical parkinsonism, especially PSP [45]. The PPN, a
mainly nondopaminergic nucleus, may be responsible, in
part, for the impaired postural stability associated with FOG.
Thus, infarction of the PPN results in FOG [46], and deep
brain stimulation of the PPN may result in improvement in
FOG [47].
Disruption of the PPNandother nondopaminergic nuclei
(cholinergic, noradrenergic) mediating postural stability,
may underlie FOG not responsive to levodopa.
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